Treatment outcomes and safety of oral β-blockers and sirolimus in children with kaposiform hemangioendothelioma: a single-center retrospective cohort study
Year: 2026
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: To describe outcomes and safety of oral β-blockers and sirolimus in children with kaposiform hemangioendothelioma (KHE). METHODS: We retrospectively reviewed children with KHE receiving oral β-blockers or sirolimus at Beijing Children's Hospital from January 2016 to April 2026. Lesion regression at fixed time points, treatment duration, treatment discontinuation, recurrence, and safety were assessed. RESULTS: = 0.003). Cumulative lesion-regression thresholds did not differ significantly through 9 months. At 9 months, >25%, >50%, and >75% regression occurred in 76.9%, 46.2%, and 23.1% with β-blockers versus 100.0%, 72.7%, and 18.2% with sirolimus, respectively. Treatment was discontinued in 9/13 and 3/11 patients (median durations, 40.0 and 18.0 months, respectively). No recurrence was observed after cessation. Safety events were reversible and manageable. CONCLUSIONS: In this cohort, both treatments were associated with improvement, but baseline imbalances limit direct comparison. β-blocker responses in predominantly younger, less symptomatic patients require confirmation in larger prospective studies.
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Award: G1436835681
OpenAlex ID: W7236814168
